We identify the health system characteristics associated with greater or lesser documentation of patients’ social determinants of health.
|Articles|January 1, 2001
The American Journal of Managed Care
- January 2001
- Volume 7
- Issue 1
Ambulatory Drug Utilization Review: Opportunities for Improved Prescription Drug Use
Advertisement
Articles in this issue
almost 26 years ago
Indirect Cost of Ischemic Heart Disease to Employersalmost 26 years ago
Disenrollment from Medicare HMOsalmost 26 years ago
A Comparison of Abciximab Use in MCO and Non-MCO Populationsalmost 26 years ago
The Employer's Perspectivealmost 26 years ago
Is the Healthcare Workforce a Barrier to Cost Containment?almost 26 years ago
Is the Healthcare Workforce a Barrier to Cost Containment?almost 26 years ago
Is the Healthcare Workforce a Barrier to Cost Containment?almost 26 years ago
Is the Healthcare Workforce a Barrier to Cost Containment?Advertisement
Related to this article
MA-to-MA switching among dually eligible beneficiaries rose sharply from 2016 to 2022, AJMC study author Grace Mackleby, PhD, found.
This moves the noncovalent BTK inhibitor into the first-line setting for certain adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.
CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.
This week in health equity and access: PMOS diagnosis, HIV lung cancer screening, transplant access, atopic dermatitis care, and value-based oncology.
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Patch testing in Malaysia finds contact dermatitis drivers in chronic hand eczema—nickel and fragrance allergy lead, while cosmetics raise polysensitization risk.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Advertisement
Advertisement
Trending on AJMC
1
Pharmacists Bridge the Vaccine Trust Gap as COVID-19 Persists
2
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
3
Who Recommends COVID-19 Vaccines Without ACIP?
4
FDA Approves Pirtobrutinib for Untreated CLL/SLL Without 17p Deletion
5